Achilles Therapeutics Plc (ACHL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 143,711 | 158,460 | 173,338 | 179,890 | 201,595 |
| TOTAL | $175,210 | $185,262 | $196,580 | $198,687 | $227,580 |
| Non-Current Assets | |||||
| PPE Net | 10,949 | 11,800 | 12,399 | 17,419 | 17,626 |
| Other Non-Current Assets | 11,748 | 10,573 | 11,379 | 11,244 | 12,512 |
| TOTAL | $22,697 | $22,373 | $23,778 | $28,663 | $30,138 |
| Total Assets | $197,907 | $207,635 | $220,358 | $227,350 | $257,718 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 6,886 | 7,650 | 5,187 | 7,516 | 6,651 |
| Accrued Expenses | 7,569 | 5,955 | 8,292 | 7,445 | 8,720 |
| TOTAL | $19,118 | $17,947 | $17,993 | $19,056 | $19,869 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 974 | 954 | 5,321 | 726 | 621 |
| TOTAL | $4,946 | $4,517 | $5,321 | $5,678 | $6,261 |
| Total Liabilities | $24,064 | $22,464 | $23,314 | $24,734 | $26,130 |
| Shareholders' Equity | |||||
| Common Shares | 54 | 54 | 54 | 54 | 54 |
| Retained earnings | -224,639 | -207,793 | -190,287 | -166,231 | -153,755 |
| Other shareholders' equity | -13,773 | -17,590 | -21,567 | -38,362 | -20,215 |
| TOTAL | $173,843 | $185,171 | $197,044 | $202,616 | $231,588 |
| Total Liabilities And Equity | $197,907 | $207,635 | $220,358 | $227,350 | $257,718 |